Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cagliflozin plus irbesartan for diabetic nephropathy
ChiCTR2000034878Phase 4Recruiting
- Sponsor
- Henan Provincial People's Hospital
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of canagliflozin and irbesartan in diabetic glomerulosclerosis (2 arms), sponsored by Henan Provincial People's Hospital. Primary endpoints: estimated glomerular filtration rate, urinary albumin-to-creatinine ratio and 1 more. Started Jul 2020; status: recruiting.
02
Drugs
canagliflozinirbesartan
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on ChiCTR2000034878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034878.